Lorbrena (lorlatinib) — Medica
Inflammatory Myofibroblastic Tumor
Initial criteria
- Patient is age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- Patient meets ONE of the following: (i) advanced, recurrent, or metastatic disease OR (ii) tumor is inoperable
Approval duration
1 year